Skip to main content

FDA Sticks to Its Naming Plan for Biologics and Biosimilars

This Bloomberg BNA Health Law article discusses the Food & Drug Administration’s (FDA) controversial guidance on the naming of biological products, designed to prevent inadvertent substitution and support safety monitoring when they are on the market. Joanne Hawana, a Mintz attorney whose practice focuses on health care, the FDA and Consumer Product Safety, is quoted in this article.


Bloomberg BNA Health Law Resource Center